RILYN Q1 2024 Earnings Significant Loss Reported Revenue Not Disclosed NJR Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency and Regulatory Execution ATNM Q1 2026 Earnings NarrowerthanExpected Loss Highlights Controlled Spending Amid Clinical Progress Compass Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Pipeline Progress Citius Oncology Q1 2026 Earnings Wide EPS Miss Highlights PreRevenue Challenges OCC Q1 2026 Earnings Net Loss of 005 Per Share Stock Climbs 788